Mbm 5: MBM 5 — MBM5.exe — Program Information

MBM Framework, Long-Term Value Created Incentives

  • Share on Facebook
  • Share on Twitter

The Koch MBM framework has five “dimensions” that guide decision making processes.  The five dimensions are, Vision, Virtue and Talent, Knowledge Process, Decision Rights, and Incentives.  All five dimensions of the MBM framework are meant to be mutually reinforcing, based on having the right people in the right places, and giving those people a right to decide based comparative advantages of skill and talent, while guided by an overarching vision.  In this article we will focus on a single case study and how Koch’s MBM was utilized to reimagine incentives.  For a more in-depth view of Koch’s Market-Based Management (MBM) framework, consider reading “Good Profit” by Charles G. Koch. 


  • Georgia-Pacific Incentives Reimagined
  • Aligning Incentives
  • How HR can Apply an MBM to Compensation

Georgia-Pacific Incentives Reimagined

In 2005, Koch Industries bought Georgia-Pacific and revitalized and transformed it by applying the Koch MBM Framework.  Georgia-Pacific (GP) traditionally rewarded people for meeting budgets and quarterly projections, as opposed to contributions to long term value.  Employees were paid based on pay grades and bonuses were capped and based on a formula.  Employees that failed to make budget did not receive bonuses, and bonuses were capped when they did meet projections.  They found that short term incentives discourage their employees from innovating. 

Under Koch Industries guidance through use of MBM incentives were reimagined.  Employee bonuses and incentives were switched to rewarding them based on their contribution to long-term value creation.  With the change, they considered not only concurrent earnings and return, but the overall building of future capabilities as a platform for creating value.  Instead of rewarding leaders on just meeting budget’s and profits, leaders are rewarded by improving culture.  They also, switch their sales force incentives form one based on volume to one based on long-term profitability, improved customer relations, and value for customers.

Aligning Incentives

When companies develop beneficial incentives, they motivate people to work harder, become more creative, and produce more value.  Beneficial incentives are mutually beneficial for customers, employees, and businesses. Employers need to learn how to use incentives to guide employees to increase their capabilities, focus and effort.  Employers should use beneficial incentives to enable their employees to grow and develop.  It requires aligning incentives to a company’s vision and interests with that of the employee. 

To align incentives, it is important financial incentives are tied to what matters towards the creation of long-term value. This requires attaching incentives to performance towards what employees are accountable and contribution towards the overall long-term creation of value.  This switch from incentivizing more than mere results to overall value creation can guide how to assign bonuses and raises. 

How HR can Apply an MBM to Compensation

For human resources, the traditional thinking about compensation and bonuses are always tied with results either annually or quarterly. However, in “Ditch the Once a Year Performance Review”, we discussed that HR should divorce compensation from performance results, rather make it a separate conversation.  MBM could help human resources to help guide how to divvy out bonuses and raises, based on a criterion separate from results of performance, instead use the long-term value employees created for the company.  It may be difficult for employers to determine the long-term value any individual creates through their work, being that some value is objective, while some is subjective. However, long-term value can be calculated to some end.  It is important to remind employers that one of the four key drivers for long-term value creation is talent. 

Investing in and properly compensating employees has a significantly impacts a company’s potential to create long-term value.  Tying an employee’s compensation to that long-term value creation will help incentivize work that is mutually beneficial for employee and employer.   This can serve as a framework in calculating bonuses and pay increases beyond mere results and an annual performance review.

Preclinical activity of MBM-5 in gastrointestinal cancer by inhibiting NEK2 kinase activity

1. Fry AM, O’Regan L, Sabir SR, Bayliss R. Cell cycle regulation by the NEK family of protein kinases. J Cell Sci. 2012;125:4423–33. doi: 10.1242/jcs.111195. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

2. Fry AM, Mayor T, Meraldi P, Stierhof YD, Tanaka K, Nigg EA. C-Nap1, a novel centrosomal coiled-coil protein and candidate substrate of the cell cycle-regulated protein kinase Nek2. J Cell Biol. 1998;141:1563–74. doi. [PMC free article] [PubMed] [Google Scholar]

3. Bahe S, Stierhof YD, Wilkinson CJ, Leiss F, Nigg EA. Rootletin forms centriole-associated filaments and functions in centrosome cohesion. J Cell Biol. 2005;171:27–33. doi: 10.1083/jcb.200504107. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Man X, Megraw TL, Lim YP. Cep68 can be regulated by Nek2 and SCF complex. Eur J Cell Biol. 2015;94:162–72. doi: 10.1016/j.ejcb.2015.01.004. [PubMed] [CrossRef] [Google Scholar]

5. Rapley J, Baxter JE, Blot J, Wattam SL, Casenghi M, Meraldi P, Nigg EA, Fry AM. Coordinate regulation of the mother centriole component nlp by nek2 and plk1 protein kinases. Mol Cell Biol. 2005;25:1309–24. doi: 10.1128/MCB.25.4.1309-1324.2005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Chen Y, Riley DJ, Zheng L, Chen PL, Lee WH. Phosphorylation of the mitotic regulator protein Hec1 by Nek2 kinase is essential for faithful chromosome segregation. J Biol Chem. 2002;277:49408–16. doi: 10.1074/jbc.M207069200. [PubMed] [CrossRef] [Google Scholar]

7. Du J, Cai X, Yao J, Ding X, Wu Q, Pei S, Jiang K, Zhang Y, Wang W, Shi Y, Lai Y, Shen J, Teng M, et al. The mitotic checkpoint kinase NEK2A regulates kinetochore microtubule attachment stability. Oncogene. 2008;27:4107–14. doi: 10.1038/onc. 2008.34. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Lou Y, Yao J, Zereshki A, Dou Z, Ahmed K, Wang H, Hu J, Wang Y, Yao X. NEK2A interacts with MAD1 and possibly functions as a novel integrator of the spindle checkpoint signaling. J Biol Chem. 2004;279:20049–57. doi: 10.1074/jbc.M314205200. [PubMed] [CrossRef] [Google Scholar]

9. Wei R, Ngo B, Wu G, Lee WH. Phosphorylation of the Ndc80 complex protein, HEC1, by Nek2 kinase modulates chromosome alignment and signaling of the spindle assembly checkpoint. Mol Biol Cell. 2011;22:3584–94. doi: 10.1091/mbc.E11-01-0012. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

10. Fu G, Ding X, Yuan K, Aikhionbare F, Yao J, Cai X, Jiang K, Yao X. Phosphorylation of human Sgo1 by NEK2A is essential for chromosome congression in mitosis. Cell Res. 2007;17:608–18. doi: 10.1038/cr.2007.55. [PubMed] [CrossRef] [Google Scholar]

11. Fletcher L, Cerniglia GJ, Yen TJ, Muschel RJ. Live cell imaging reveals distinct roles in cell cycle regulation for Nek2A and Nek2B. Biochim Biophys Acta. 2005;1744:89–92. doi: 10.1016/j.bbamcr.2005.01.007. [PubMed] [CrossRef] [Google Scholar]

12. Weiss MM, Kuipers EJ, Postma C, Snijders AM, Pinkel D, Meuwissen SG, Albertson D, Meijer GA. Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol. 2004;26:307–17. doi. [PMC free article] [PubMed] [Google Scholar]

13. Suzuki K, Kokuryo T, Senga T, Yokoyama Y, Nagino M, Hamaguchi M. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin. Cancer Sci. 2010;101:1163–9. doi: 10.1111/j.1349-7006.2010.01504.x. [PubMed] [CrossRef] [Google Scholar]

14. Neal CP, Fry AM, Moreman C, McGregor A, Garcea G, Berry DP, Manson MM. Overexpression of the Nek2 kinase in colorectal cancer correlates with beta-catenin relocalization and shortened cancer-specific survival. J Surg Oncol. 2014;110:828–38. doi: 10.1002/jso.23717. [PubMed] [CrossRef] [Google Scholar]

15. Zeng YR, Han ZD, Wang C, Cai C, Huang YQ, Luo HW, Liu ZZ, Zhuo YJ, Dai QS, Zhao HB, Liang YX, Zhong WD. Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer. BMC Urol. 2015;15:90. doi: 10.1186/s12894-015-0085-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Hayward DG, Clarke RB, Faragher AJ, Pillai MR, Hagan IM, Fry AM. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res. 2004;64:7370–6. doi: 10.1158/0008-5472.CAN-04-0960. [PubMed] [CrossRef] [Google Scholar]

17. Tsunoda N, Kokuryo T, Oda K, Senga T, Yokoyama Y, Nagino M, Nimura Y, Hamaguchi M. Nek2 as a novel molecular target for the treatment of breast carcinoma. Cancer Sci. 2009;100:111–6. doi: 10.1111/j.1349-7006.2008.01007.x. [PubMed] [CrossRef] [Google Scholar]

18. Xia J, Franqui Machin R, Gu Z, Zhan F. Role of NEK2A in human cancer and its therapeutic potentials. Biomed Res Int. 2015;2015:862461. doi: 10.1155/2015/862461. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

19. Fang Y, Zhang X. Targeting NEK2 as a promising therapeutic approach for cancer treatment. Cell Cycle. 2016;15:895–907. doi: 10.1080/15384101.2016.1152430. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

20. Kokuryo T, Senga T, Yokoyama Y, Nagino M, Nimura Y, Hamaguchi M. Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma. Cancer Res. 2007;67:9637–42. doi: 10.1158/0008-5472.CAN-07-1489. [PubMed] [CrossRef] [Google Scholar]

21. Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z, Shi L, Zangari M, Miles R, et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013;23:48–62. doi: 10.1016/j.ccr.2012.12.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. Zhang MX, Xu XM, Zhang P, Han NN, Deng JJ, Yu TT, Gan YY, He XQ, Long ZX. Effect of silencing NEK2 on biological behaviors of HepG2 in human hepatoma cells and MAPK signal pathway. Tumour Biol. 2015 doi: 10.1007/s13277-015-3993-y.. [PubMed] [CrossRef] [Google Scholar]

23. Cappello P, Blaser H, Gorrini C, Lin DC, Elia AJ, Wakeham A, Haider S, Boutros PC, Mason JM, Miller NA, Youngson B, Done SJ, Mak TW. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells. Oncogene. 2014;33:2375–84. doi: 10.1038/onc.2013.183. [PubMed] [CrossRef] [Google Scholar]

24. Lee J, Gollahon L. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triplenegative breast cancer cells. Int J Oncol. 2013;42:839–47. doi: 10.3892/ijo.2013.1788. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

25. Rellos P, Ivins FJ, Baxter JE, Pike A, Nott TJ, Parkinson DM, Das S, Howell S, Fedorov O, Shen QY, Fry AM, Knapp S, Smerdon SJ. Structure and regulation of the human Nek2 centrosomal kinase. J Biol Chem. 2007;282:6833–42. doi: 10.1074/jbc.M609721200. [PubMed] [CrossRef] [Google Scholar]

26. Emmitte KA, Adjabeng GM, Andrews CW, Alberti JG, Bambal R, Chamberlain SD, Davis-Ward RG, Dickson HD, Hassler DF, Hornberger KR, Jackson JR, Kuntz KW, Lansing TJ, et al. Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. Bioorg Med Chem Lett. 2009;19:1694–7. doi: 10.1016/j.bmcl.2009.01.094. [PubMed] [CrossRef] [Google Scholar]

27. Hayward DG, Newbatt Y, Pickard L, Byrne E, Mao G, Burns S, Sahota NK, Workman P, Collins I, Aherne W, Fry AM. Identification by high-throughput screening of viridin analogs as biochemical and cell-based inhibitors of the cell cycle-regulated nek2 kinase. J Biomol Screen. 2010;15:918–27. doi: 10.1177/1087057110376537. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

28. Whelligan DK, Solanki S, Taylor D, Thomson DW, Cheung KM, Boxall K, Mas-Droux C, Barillari C, Burns S, Grummitt CG, Collins I, van Montfort RL, Aherne GW, et al. Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization. J Med Chem. 2010;53:7682–98. doi: 10.1021/jm1008727. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

29. Solanki S, Innocenti P, Mas-Droux C, Boxall K, Barillari C, van Montfort RL, Aherne GW, Bayliss R, Hoelder S. Benzimidazole inhibitors induce a DFG-out conformation of never in mitosis gene A-related kinase 2 (Nek2) without binding to the back pocket and reveal a nonlinear structure-activity relationship. J Med Chem. 2011;54:1626–39. doi: 10.1021/jm1011726. [PubMed] [CrossRef] [Google Scholar]

30. Innocenti P, Cheung KM, Solanki S, Mas-Droux C, Rowan F, Yeoh S, Boxall K, Westlake M, Pickard L, Hardy T, Baxter JE, Aherne GW, Bayliss R, et al. Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activity. J Med Chem. 2012;55:3228–41. doi: 10.1021/jm201683b. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

31. Henise JC, Taunton J. Irreversible Nek2 kinase inhibitors with cellular activity. J Med Chem. 2011;54:4133–46. doi: 10.1021/jm200222m. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

32. Hu CM, Zhu J, Guo XE, Chen W, Qiu XL, Ngo B, Chien R, Wang YV, Tsai CY, Wu G, Kim Y, Lopez R, Chamberlin AR, et al. Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism. Oncogene. 2015;34:1220–30. doi: 10.1038/onc.2014.67. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

33. Faragher AJ, Fry AM. Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles. Mol Biol Cell. 2003;14:2876–89. doi: 10.1091/mbc.E03-02-0108. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

34. Wu G, Qiu XL, Zhou L, Zhu J, Chamberlin R, Lau J, Chen PL, Lee WH. Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. Cancer Res. 2008;68:8393–9. doi: 10.1158/0008-5472.CAN-08-1915. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

35. Mardin BR, Lange C, Baxter JE, Hardy T, Scholz SR, Fry AM, Schiebel E. Components of the Hippo pathway cooperate with Nek2 kinase to regulate centrosome disjunction. Nat Cell Biol. 2010;12:1166–76. doi: 10.1038/ncb2120. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

36. Musacchio A. The Molecular Biology of Spindle Assembly Checkpoint Signaling Dynamics. Curr Biol. 2015;25:R1002–18. doi: 10.1016/j.cub.2015.08.051. [PubMed] [CrossRef] [Google Scholar]

37. Andreassen PR, Lohez OD, Margolis RL. G2 and spindle assembly checkpoint adaptation, and tetraploidy arrest: implications for intrinsic and chemically induced genomic instability. Mutat Res. 2003;532:245–53. doi. [PubMed] [Google Scholar]

38. Jeong AL, Lee S, Park JS, Han S, Jang CY, Lim JS, Lee MS, Yang Y. Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity. J Biol Chem. 2014;289:28–40. doi: 10.1074/jbc.M113.507954. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

39. Zhu H, Luo P, Fu Y, Wang J, Dai J, Shao J, Yang X, Chang L, Weng Q, Yang B, He Q. Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin. Oncotarget. 2015;6:3254–67. doi: 10.18632/oncotarget.2410. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

40. Nakayama R, Zhang YX, Czaplinski JT, Anatone AJ, Sicinska ET, Fletcher JA, Demetri GD, Wagner AJ. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget. 2016;7:16581–92. doi: 10.18632/oncotarget.7667. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Replica FR BMW B5181 7,5R17 5*112 ET45 d66,6 MBM [20/63/52/275] 1/2/X1/X2 style 760M

Please indicate the city where you are located!

  • Yekaterinburg
  • Chrysostom
  • Ishim
  • Kamensk-Uralsky
  • Kogalym
  • Krasnoufimsk
  • nine0018 Krasnoyarsk

  • Kyshtym
  • Langepas
  • Magnitogorsk
  • Megion
  • Miass
  • Nefteyugansk
  • Nizhnevartovsk
  • Nizhny Tagil
  • nine0036 Novosibirsk

  • Nyagan
  • Ozersk
  • Pervouralsk
  • Perm
  • Revda
  • Satka
  • Serov
  • Snezhinsk
  • nine0054 Sredneuralsk

  • Surgut
  • Sysert
  • Tobolsk
  • Trekhgorny
  • Troitsk
  • Tyumen
  • Uray
  • Ufa
  • nine0072 Uchaly

  • Khanty-Mansiysk
  • Chebarkul
  • Chelyabinsk
  • Yugorsk
  • Yuzhnouralsk
  • Rainbow

how to develop a business idea in 5 days

Everything for Startups, Who will teach? nine0003

  • Published

    Varvara Mikhalcheva



In 2017, the MBM Startup School was launched. The free program is aimed at developing the practical skills of aspiring entrepreneurs. Since the launch of the MBM Startup School, about 7,000 Muscovites have been trained, 44% of them have opened or plan to open their own business in the capital. nine0003

How is the training at the MBM Startup School? Classes are held in full-time format at the site of the Russian School of Management. The entire course is designed for 5 days, each meeting lasts 4.5 hours.

Pupils discuss their ideas among like-minded people and refine them. Practitioners share their experience in business development in Moscow, tell aspiring entrepreneurs about the basics of marketing, PR tools, and legal aspects of doing business. The classes also discuss current measures to support small and medium-sized businesses in the capital. nine0003

Graduates of the course receive certificates of completion of training at the MBM Startup School.

Training program. Classes at the MBM Startup School total 40 academic hours. For convenience, the entire program is divided into 10 modules.

  1. Team building (team building).
  2. Networking and testing ideas (how the «six handshakes» theory works when looking for investors and partners).
  3. Business modeling (calculation of the financial plan, selection of construction tools, testing of the final version of the project). nine0007
  4. Business planning (how to set goals and achieve them).
  5. Marketing (advertising budget, digital marketing of the project, plan for launching the first advertising campaign).
  6. Sales (Universal Strategies, Zero Budget Sales, Franchise Business Scaling).
  7. Legal and accounting aspects (accounting from A to Z).
  8. Project management (roadmap and planners, main implementation points).
  9. Project preparation. nine0007
  10. Project protection.

In addition, course graduates will receive personal advice and assistance in registering an individual entrepreneur or LLC.

When will the next training take place at the MBM Startup School? Training takes place every week. Enrollment for next week opens on Mondays. You can register for the event on the official website of the MBM Startup School.

MBM Startup School online course. If full-time classes are not suitable for you, then training can be done remotely. In 2020, during the coronavirus pandemic, the MBM Startup School online course was launched. Every Monday, registration for the following week opens. nine0003

The online course program consists of five webinar modules lasting 1.5 hours:

  1. Business idea generation.
  2. Relevance of business modeling and business planning for start-up projects.
  3. Project management from idea to implementation.
  4. Marketing for startups.
  5. Legal issues, taxes, finances.

After each lesson, students receive practical tasks for self-practice.